Omeros (OMER) Non-Current Deffered Revenue (2012 - 2018)
Omeros (OMER) posted Non-Current Deffered Revenue of $8.2 million for Q4 2018, down 1.78% sequentially from $8.3 million in Q3 2018, and down 6.21% YoY from $8.7 million in Q4 2017.
Analysis
Omeros (OMER) Non-Current Deffered Revenue (2012 - 2018) Analysis & Trends
Omeros has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $8.2 million in Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 6.21% year-over-year to $8.2 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $8.2 million (down 6.21% YoY) and the FY2018 annual result came in at $8.2 million, down 6.21% from the prior year.
- Non-Current Deffered Revenue slipped to $8.2 million in Q4 2018 per OMER's latest filing, from $8.3 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $9.2 million in Q1 2016 and troughed at $8.2 million in Q4 2018.
- A 5-year average of $8.9 million and a median of $9.0 million in 2017 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2014 and 2018: Non-Current Deffered Revenue soared 122.99% in 2014, then slipped 6.21% in 2018.
- Over 5 years, Non-Current Deffered Revenue stood at $9.0 million in 2014, then climbed by 1.73% to $9.2 million in 2015, then retreated by 0.71% to $9.1 million in 2016, then slipped by 4.64% to $8.7 million in 2017, then retreated by 6.21% to $8.2 million in 2018.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $8.2 million, $8.3 million, and $8.5 million for Q4 2018, Q3 2018, and Q2 2018 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 8.18 Mn |
| Sep 30, 2018 | 8.33 Mn |
| Jun 30, 2018 | 8.45 Mn |
| Mar 31, 2018 | 8.58 Mn |
| Dec 31, 2017 | 8.72 Mn |
| Sep 30, 2017 | 8.84 Mn |
| Jun 30, 2017 | 8.94 Mn |
| Mar 31, 2017 | 9.04 Mn |
| Dec 31, 2016 | 9.14 Mn |
| Sep 30, 2016 | 9.19 Mn |
| Jun 30, 2016 | 9.21 Mn |
| Mar 31, 2016 | 9.22 Mn |
| Dec 31, 2015 | 9.21 Mn |
| Sep 30, 2015 | 9.17 Mn |
| Jun 30, 2015 | 9.13 Mn |
| Mar 31, 2015 | 9.09 Mn |
| Dec 31, 2014 | 9.05 Mn |
| Sep 30, 2014 | 8.94 Mn |
| Jun 30, 2014 | 8.67 Mn |
| Mar 31, 2014 | 8.41 Mn |